Dave L. Dixon

9.4k total citations · 4 hit papers
151 papers, 3.7k citations indexed

About

Dave L. Dixon is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Dave L. Dixon has authored 151 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Surgery, 54 papers in Cardiology and Cardiovascular Medicine and 38 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Dave L. Dixon's work include Lipoproteins and Cardiovascular Health (42 papers), Pharmaceutical Practices and Patient Outcomes (30 papers) and Health Systems, Economic Evaluations, Quality of Life (29 papers). Dave L. Dixon is often cited by papers focused on Lipoproteins and Cardiovascular Health (42 papers), Pharmaceutical Practices and Patient Outcomes (30 papers) and Health Systems, Economic Evaluations, Quality of Life (29 papers). Dave L. Dixon collaborates with scholars based in United States, Italy and Saudi Arabia. Dave L. Dixon's co-authors include Antonio Abbate, Benjamín Van Tassell, Salvatore Carbone, Leo F. Buckley, Aldo Bonaventura, Fabrizio Montecucco, Alessandra Vecchié, Evan M. Sisson, Lorenzo Dagna and Benjamín W. Van Tassell and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Nature reviews. Immunology.

In The Last Decade

Dave L. Dixon

138 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

2021 619 citations Dave L. Dixon, Benjamín Van Tassell et al. profile →
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction

2023 209 citations Dave L. Dixon et al. profile →
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice

2024 127 citations Dave L. Dixon, Terry A. Jacobson et al. Journal of clinical lipidology profile →
Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024

2024 42 citations Dave L. Dixon, Terry A. Jacobson et al. Journal of clinical lipidology profile →

Peers

Countries citing papers authored by Dave L. Dixon

Since Specialization

Citations

This map shows the geographic impact of Dave L. Dixon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dave L. Dixon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dave L. Dixon more than expected).

Fields of papers citing papers by Dave L. Dixon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dave L. Dixon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dave L. Dixon. The network helps show where Dave L. Dixon may publish in the future.

Co-authorship network of co-authors of Dave L. Dixon

This figure shows the co-authorship network connecting the top 25 collaborators of Dave L. Dixon. A scholar is included among the top collaborators of Dave L. Dixon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dave L. Dixon. Dave L. Dixon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chronobiology of meal timing in early-stage hypertension: a controlled feeding pilot study investigating the effects on renal and vascular function 2025 ·Journal of Applied Physiology ·(unknown), (unknown), (unknown), Paula Rodriguez‐Miguelez, Dave L. Dixon, Youngdeok Kim, Salvatore Carbone, Danielle L. Kirkman	0
2	Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society 2025 ·Journal of clinical lipidology ·Vera Bittner, Sunny A. Linnebur, Dave L. Dixon, Daniel E. Forman, Ariel R. Green, Terry A. Jacobson, Ariela R. Orkaby, Joseph J. Saseen, Salim S. Virani	3
3	Evaluation of lipid-lowering therapy in patients with elevated lipoprotein(a) levels 2025 ·Journal of clinical lipidology ·Michael S. Kelly, (unknown), (unknown), (unknown), Pablo Ramírez, Dave L. Dixon	0
4	Chrono‐nutrition for hypertension 2024 ·Diabetes/Metabolism Research and Reviews ·(unknown), Dave L. Dixon, Danielle L. Kirkman	5
5	Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association 2024 ·Journal of clinical lipidology ·Anandita Agarwala, Dave L. Dixon, Eugenia Gianos, (unknown), Erin D. Michos, Priyanka Satish, Kim K. Birtcher, Lynne T. Braun, (unknown), Karol E. Watson, Robert A. Wild, Laxmi S. Mehta	14
6	Effect of pharmacist interventions on the management of overweight and obesity: A systematic review 2024 ·Journal of the American Pharmacists Association ·(unknown), Emily A. Cook, (unknown), Roy Brown, Dave L. Dixon	5
7	Longitudinal medication adherence group-based trajectories of aging adults in the US: A retrospective analysis using monthly proportion of days covered calculations 2023 ·Research in Social and Administrative Pharmacy ·(unknown), Julie A. Patterson, Dave L. Dixon, Norman V. Carroll, (unknown), Andrew J. Barnes, Karen B. Farris, David A. Holdford	3
8	Job satisfaction among board-certified pharmacists in Virginia 2023 ·Journal of the American Pharmacists Association ·(unknown), (unknown), Teresa M. Salgado, Dave L. Dixon, Evan M. Sisson, (unknown)	2
9	Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies 2023 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), Azita H. Talasaz, Anurag Mehta, Michael S. Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon	21
10	Comparison of Safety and Biological Efficacy of Anakinra (Kineret) Dispensed in Polycarbonate Plastic versus Borosilicate Glass Syringes: A Patient-Level Analysis of VCUART2 and VCUART3 Clinical Trials 2023 ·Journal of Pharmacology and Experimental Therapeutics ·Azita H. Talasaz, Robin Sculthorpe, (unknown), Michael J. Lipinski, Charlotte A. Roberts, Roshanak Markley, Cory R. Trankle, Justin M. Canada, George F. Wohlford, Michele Golino, Dave L. Dixon, Benjamín W. Van Tassell, Antonio Abbate	1
11	Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program and impact of the COVID-19 pandemic on program delivery 2022 ·Journal of the American Pharmacists Association ·(unknown), Evan M. Sisson, Dave L. Dixon	3
12	Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events 2022 ·Hypertension ·Leo F. Buckley, William L. Baker, Benjamín Van Tassell, Jordana B. Cohen, (unknown), Adam P. Bress, Dave L. Dixon	24
13	An ounce of prevention is worth a pound of cure: considerations for pharmacists delivering the National Diabetes Prevention Program 2021 ·Pharmacy Practice ·Dave L. Dixon, Evan M. Sisson, (unknown), (unknown), Teresa M. Salgado	3
14	Factors associated with antihypertensive monotherapy among US adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, National Health and Nutrition Examination Survey 2013-2018 2021 ·American Heart Journal ·Alexander R. Zheutlin, Catherine G. Derington, Jordan B. King, (unknown), Jennifer S. Herrick, Dave L. Dixon, Jordana B. Cohen, Daichi Shimbo, Ian M. Kronish, Joseph J. Saseen, Paul Muntner, Andrew E. Moran, Adam P. Bress	3
15	Development and feasibility of a community pharmacy–driven 24-hour ambulatory blood pressure monitoring service 2020 ·Journal of the American Pharmacists Association ·Dave L. Dixon, Julie A. Patterson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Teresa M. Salgado, David A. Holdford	5
16	Primary healthcare policy and vision for community pharmacy and pharmacists in the United States 2020 ·Pharmacy Practice ·Teresa M. Salgado, Meagen Rosenthal, Antoinette B. Coe, (unknown), Dave L. Dixon, Karen B. Farris	23
17	Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series 2019 ·Pharmacy Practice ·(unknown), John D. Bucheit, Pramit Nadpara, Dave L. Dixon, (unknown), (unknown), Evan M. Sisson	17
18	To tweet or not to tweet? A primer on social media for pharmacists 2019 ·JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY ·Dave L. Dixon, Brent N. Reed	7
19	Pharmacist‐physician collaborative care model and time to goal blood pressure in the uninsured population 2017 ·Journal of Clinical Hypertension ·Dave L. Dixon, Evan M. Sisson, (unknown), Benjamín Van Tassell, Pramit Nadpara, Daniel Carl, Alan Dow	25
20	Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review 2017 ·Pharmacy Practice ·(unknown), Dave L. Dixon, Vimal Mishra, Evan M. Sisson, Teresa M. Salgado	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact